| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2153812 | Nuclear Medicine and Biology | 2012 | 5 Pages |
Abstract
[123I] mZIENT demonstrates good test-retest reproducibility; and initial displacement studies suggest that this compound is highly selective for SERT. Overall, this radioligand has favorable characteristics for use in drug development studies and/or longitudinal studies interrogating SERT.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
![In vivo evaluation of [123I]mZIENT as a SPECT radioligand for the serotonin transporter](/preview/png/2153812.png "First Page Preview: In vivo evaluation of [123I]mZIENT as a SPECT radioligand for the serotonin transporter")
Authors
Jeffery Batis, Olivier Barret, David Alagille, Andrei O. Koren, Jeffrey S. Stehouwer, Kelly Cosgrove, Mark Goodman, John Seibyl, Gilles Tamagnan,